Sunshine Guojian Pharmaceutical Shanghai (SHA:688336) received the approval of China's drug administrator to begin clinical trials for SSGJ-627 injection.
The drug is a monoclonal antibody injection targeting ulcerative colitis, according to a Thursday filing with the Shanghai bourse.
Shares of the pharmaceutical company were down 6% in recent trade.